Baidu
map

国务院:取消国产药品注册初审等25项行政许可事项

2019-03-08 佚名 人民政府网

日前,国务院下发《关于取消和下放一批行政许可事项的决定(国发〔2019〕6号)》的文件。

日前,国务院下发《关于取消和下放一批行政许可事项的决定(国发〔2019〕6号)》的文件。

文件指出,取消25项行政许可事项,其中包括取消国产药品注册初审和假肢和矫形器(辅助器具)生产装配企业资格认定。

国务院要求,各地区、各有关部门要抓紧做好取消和下放行政许可事项的落实和衔接工作,制定完善事中事后监管措施,采取“双随机、一公开”监管、重点监管、信用监管、“互联网+监管”等方式,确保放得开、接得住、管得好。自本决定发布之日起20个工作日内,各有关部门要按规定向社会公布事中事后监管细则,并加强宣传解读和督促落实。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085266, encodeId=cb7d208526619, content=<a href='/topic/show?id=b72b40e5250' target=_blank style='color:#2F92EE;'>#国产药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40752, encryptionId=b72b40e5250, topicName=国产药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Oct 23 13:11:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440617, encodeId=8ffd144061e87, content=<a href='/topic/show?id=eeeb8e444e6' target=_blank style='color:#2F92EE;'>#药品注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87444, encryptionId=eeeb8e444e6, topicName=药品注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f64741524, createdName=1508842480_96220438, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556849, encodeId=939e1556849ab, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362270, encodeId=7efd3622e0c7, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Mar 08 19:02:10 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085266, encodeId=cb7d208526619, content=<a href='/topic/show?id=b72b40e5250' target=_blank style='color:#2F92EE;'>#国产药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40752, encryptionId=b72b40e5250, topicName=国产药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Oct 23 13:11:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440617, encodeId=8ffd144061e87, content=<a href='/topic/show?id=eeeb8e444e6' target=_blank style='color:#2F92EE;'>#药品注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87444, encryptionId=eeeb8e444e6, topicName=药品注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f64741524, createdName=1508842480_96220438, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556849, encodeId=939e1556849ab, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362270, encodeId=7efd3622e0c7, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Mar 08 19:02:10 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085266, encodeId=cb7d208526619, content=<a href='/topic/show?id=b72b40e5250' target=_blank style='color:#2F92EE;'>#国产药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40752, encryptionId=b72b40e5250, topicName=国产药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Oct 23 13:11:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440617, encodeId=8ffd144061e87, content=<a href='/topic/show?id=eeeb8e444e6' target=_blank style='color:#2F92EE;'>#药品注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87444, encryptionId=eeeb8e444e6, topicName=药品注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f64741524, createdName=1508842480_96220438, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556849, encodeId=939e1556849ab, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362270, encodeId=7efd3622e0c7, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Mar 08 19:02:10 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
    2019-03-10 zhyy93
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085266, encodeId=cb7d208526619, content=<a href='/topic/show?id=b72b40e5250' target=_blank style='color:#2F92EE;'>#国产药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40752, encryptionId=b72b40e5250, topicName=国产药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ebc122, createdName=yankaienglish, createdTime=Wed Oct 23 13:11:00 CST 2019, time=2019-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440617, encodeId=8ffd144061e87, content=<a href='/topic/show?id=eeeb8e444e6' target=_blank style='color:#2F92EE;'>#药品注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87444, encryptionId=eeeb8e444e6, topicName=药品注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f64741524, createdName=1508842480_96220438, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556849, encodeId=939e1556849ab, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Sun Mar 10 05:11:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362270, encodeId=7efd3622e0c7, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Fri Mar 08 19:02:10 CST 2019, time=2019-03-08, status=1, ipAttribution=)]
    2019-03-08 清风拂面

    谢谢分享学习

    0

相关资讯

药品注册审评审批效率进一步提升

5月23日,国家药品监督管理局、国家卫生健康委员会联合公布的《关于优化药品注册审评审批有关事宜的公告》(以下简称《公告》),围绕提高创新药上市审批效率、科学简化审批程序,推出一系列重要政策措施。

第27批拟被纳入优先审评药品名单出炉 26药品入选

CDE官网公示了第二十七批拟纳入优先审评程序药品注册申请名单,其中,12药品为新药上市,9药品为新药临床,其余5药品为仿制药上市申请。

通过一致性评价产品医保优惠政策何时落地?

据第一批一致性评价品种出炉已经过去了半个月时间,招标、医保等层面的配套政策并没有如业界期望般随之发布。E药经理人多方采访了解到的信息是:已出台的利好招标规则卡在了招标周期,人社部则在权衡是否给这部分品种开“特殊通道”。还有一个问题摆在CFDA面前,即如何监管才能保证一致性评价不变成“一次性评价”?

医保控费驱动3大产业变迁

​政策变革之下,医药企业未来的发展动力在何方?医药行业细分领域的命运将如何?哪些企业将在内生和外延推动下迎来利好?

快来看!这些药品和疫苗的注册申请拟纳入优先审评程序啦!

国家食品药品监督管理总局药品审评中心2018年4月23日发布“拟纳入优先审评程序药品注册申请的公示(第二十八批)”

10省试点,这项医药政策要全国铺开?

MAH制度即药品上市许可持有人制度的试点始于2016年6月国务院办公厅印发《药品上市许可持有人制度试点方案》,在北京、天津、河北、上海、江苏、浙江、福建、山东、广东、四川等10个省(市)开展药品上市许可持有人制度试点,试点将实施至2018年11月4日。

Baidu
map
Baidu
map
Baidu
map